M de Boer-Dennert - Concepedia

Concepedia

Author

M de Boer-Dennert

Rotterdam University of Applied Sciences

Also Known As

M de Boer-Dennert, M. d. Boer-Dennert, M. de Boer-Dennert, Maureen de Boer-Dennert

34

Publications

1.7K

Citations

19

H-Index

30

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Cancer Institute Slotervaartziekenhuis The Netherlands Cancer Institute Utrecht University

MD

About

M de Boer-Dennert is an author at Rotterdam University of Applied Sciences specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.3K
2	Health Sciences	5	5	222
3	Cell Biology	2	2	165
4	Biostatistics	1	1	31
5	Immunology	1	1	119

M de Boer-Dennert

×

24

Publications

1.7K

Citations

19

H-Index

	Year	Citations
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists M de Boer-Dennert, Ronald de Wit, PIM Schmitz, British Journal of Cancer OncologyPatient PerceptionsPharmacologyPharmacotherapyMetronomic Chemotherapy	1997	375
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours JHM Schellens, Jun Ma, A.S.T. Planting, British Journal of Cancer Tumour ResponseOncogenic AgentMedicineSolid TumoursPathology	1996	146
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor JHM Schellens, G.J. Creemers, Hilde Rosing, British Journal of Cancer New TopoisomerasePharmacologyPharmacotherapyAnti-cancer AgentDrug Development	1996	130
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor Jaap Verweij, Birthe Lund, Jos H. Beijnen, Annals of Oncology Pharmaceutical ScienceNew TopoisomeraseMedicinePharmacokinetics StudyPharmacotherapy	1993	123
Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Johanneke E.A. Portielje, Wim H.J. Kruit, Martin Schüler, PubMed UrologyGenitourinary CancerMedicineImmunologyClinical Trials	1999	119
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors A. S. T. Planting, Pieter Sonneveld, Ate van der Gaast, Cancer Chemotherapy and Pharmacology OncologyMedicineAdvanced Solid TumorsMdr Converter Gf120918Anti-cancer Agent	2004	106
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks L.J.C. van Warmerdam, Jaap Verweij, Jan H.M. Schellens, Cancer Chemotherapy and Pharmacology Pharmaceutical SciencePharmacological StudyMedicinePharmacotherapyPharmacology	1995	94
Phase I and Pharmacologic Study of the Novel Indoloquinone Bioreductive Alkylating Cytotoxic Drug E09 Jan H.M. Schellens, André Planting, B.A.C. van Acker, JNCI Journal of the National Cancer Institute	1994	74
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. L. Pronk, Jan H.M. Schellens, A.S.T. Planting, Journal of Clinical Oncology	1997	66
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. G.J. Creemers, C J Gerrits, Jan H.M. Schellens, Journal of Clinical Oncology	1996	65

Page 1